Nacuity Says First Patient Dosed in Global Phase 3 Trial
Nacuity Pharmaceuticals announced that the first patient has been dosed in a global confirmatory Phase 3 trial of NPI-001 tablets for retinitis pigmentosa associated with Usher syndrome.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.